Samil Pharmaceutical Co 000520.KS · KRW

Its shares trade on KRX under the ticker 000520.KS. It has been listed since 29 May 1985. In the fiscal year to 31 December 2025, it reported revenue of ₩210.25bn and a net loss of ₩34.66bn. At that date it held total assets of ₩371.60bn and shareholders' equity of ₩133.26bn.

SAMIL PHARMACEUTICAL Co., Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The firm distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.

Figures and description from our data supplier, not checked against the company's own report.

• V.S. RamPresident
• Seung Beom HuhChief Executive Officer, Director, since 2013
• Bu Hwan GohVice President, Director
• Jong Pyo HongAssistant Managing Director
• Gi Dong KimInternal Auditor
• Ms. Jin Suk KimAssistant Managing Director
• Tae Gyeong KimAssistant Managing Director
• Gyeong Cheol OhAssistant Managing Director
• Gi Jeong LeeDirector
• Jong Nam KimNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.